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Introduction
Alzheimer's disease is one of the most common forms of neurological disorders affecting the elderly and clinically manifests itself by a gradual decline of cognitive function. Pathologically, Alzheimer's disease is characterized by the deposition of extracellular protein aggregates of amyloid-b, forming senile plaques, and neurofibrillary tangles containing phosphorylated tau (pTau) in the brain parenchyma Brion, 1998; Perl, 2010) . In the majority of cases, amyloid-b accumulates in the vasculature, a process that is referred to as cerebral amyloid angiopathy (CAA). Depending on the type of vessels affected, distinction is made between CAA with and CAA without capillary involvement; termed CAA type 1 or capillary CAA and CAA type 2, respectively (Thal et al., 2002) . CAA type 1 can be accompanied by other small vessel disorders, such as micro-embolisms, or by vascular lesions, such as infarcts, haemorrhages, white matter lesions, lacunas and microcirculatory changes, together attributing to cognitive decline (Olichney et al., 1997 (Olichney et al., , 2000 . These vascular lesions, when presented together with vascular amyloid deposition, contribute to the clinical characteristics of patients with vascular cognitive impairment (Dichgans and Leys, 2017) .
CAA in itself is increasingly recognized as a major contributor to Alzheimer's disease pathogenesis (Ghiso et al., 2010) . Various vascular risk factors, such as ageing, atherosclerosis, diabetes mellitus, and stroke are known to further enhance the risk to develop Alzheimer's disease (Gorelick, 2004) . Together, these vascular events may result in a diminished response to vasodilators, reduced cerebrovascular perfusion and, ultimately, local hypoxia (Aliev et al., 2003) . Chronic cerebral hypoperfusion and amyloid accumulation also induce cerebral angiogenesis, resulting in the formation of dysfunctional and permeable cerebral microvessels (Biron et al., 2011) .
Notably, we and others have shown evidence of a decline in blood-brain barrier function in capillary CAA, a process that may further promote disease progression (Carrano et al., 2011 (Carrano et al., , 2012 Obermeier et al., 2013; Zhao et al., 2015; Chakraborty et al., 2017) . Under healthy conditions, the brain endothelial cells that form the blood-brain barrier act as a highly selective barrier that maintains the homeostasis of the CNS, a process that is essential for optimal neuronal function (Ballabh et al., 2004; Blanchette and Daneman, 2015) . Multiple studies have shown a critical role for astrocytes in controlling blood-brain barrier function (Luissint et al., 2012) . Under pathological conditions, reactive astrocytes may impair neuroprotective blood-brain barrier properties, thereby contributing to clinical progression in different neurological diseases (Argaw et al., 2009; Mizee and de Vries, 2013) . Identification of factors released by reactive astrocytes that induce blood-brain barrier dysfunction under pathological conditions such as capillary CAA may provide new ways to improve neurovascular integrity.
In capillary CAA, local hypoxic events, resulting from impaired cerebral perfusion, may affect astrocytes to become reactive through the activation of numerous molecular pathways (Liu et al., 2012; Marina et al., 2016) . Reactive astrocytes produce pro-angiogenic factors such as basic fibroblast growth factor and vascular endothelial growth factor (VEGF), which co-localize with vascular amyloid-b depositions (Siedlak et al., 1991; Yang et al., 2004; Ahn et al., 2010) . Moreover, thrombin, also secreted by activated glial cells, may accumulate on the vessel wall and act synergistically with VEGF by inducing the expression of its receptors (Tsopanoglou and Maragoudakis, 1999) . Indeed, angiogenic vascular remodelling and increased vascular density were observed in post-mortem human brain tissues (Desai et al., 2009) , although underlying mechanisms remain to be explored.
Recent evidence from oncological studies illustrates that hypoxia mediates the secretion of angiopoietin-like 4 (ANGPTL4), a factor that has a key role in angiogenesis (Le Jan et al., 2003) . ANGPTL4 is a member of the angiogenic-regulating secreted protein superfamily, which has similarity to the angiopoietin family (Zhu et al., 2012) . Recent studies indicate that ANGPTL4 can act as a potent angiogenic mediator and may serve as a biomarker for pathological neovascularization in the retina and in tumour tissues (Dong et al., 2017; Jee et al., 2017) , illustrating its relevance in disease processes.
Based on the potent role of ANGPTL4 in the process of angiogenesis and its regulation under hypoxic conditions, we hypothesized that ANGPTL4 plays a role in the pathophysiology of capillary CAA. Here, we identified ANGPTL4 as a potent inducer of cerebral neovascularization and provide evidence that it may serve as diagnostic biomarker in patients with clinically assessed vascular cognitive complaints.
Materials and methods

Ethics approval and consent to participate
Written informed consent was obtained from all participants before inclusion in the study. The medical ethics committee approved the study.
Immunohistochemistry
Immunohistochemistry was performed using 5-mm thick sections of formalin fixed paraffin-embedded tissue. To quench endogenous peroxidase activity, tissues were treated with 0.3% H 2 O 2 in phosphate-buffered saline (PBS) for 20 min. Antigen retrieval was performed using sodium citrate buffer (pH 6) for 20 min. Sections were incubated overnight at 4 C with anti-ANGPTL4 antibody (Abcam) or anti-carbonic anhydrase IX (CA IX) (Abcam), diluted in PBS containing 1% of bovine serum albumin (BSA). Sections were subsequently stained with EnVision horseradish peroxidase (Dako) for 30 min followed by 3,3 0 diaminobenzidine tetrahydrochloride dihydrate (DAB; Dako). Sections were rinsed in tap water and counterstained with haematoxylin for 1 min. After extensive washing in tap water, sections were dehydrated in a series of ethanol and xylene baths and mounted with Entellan Õ (Merck).
Immunofluorescence
To determine the cellular source of ANGPTL4, immunofluorescent labelling was performed. Sections were deparaffinized using a series of xylene and ethanol baths and rehydrated using water. For fluorescent labelling, sections were incubated overnight at 4 C with anti-ANGPTL4 antibody (Abcam) and biotinylated ULEX Europaeus Agglutinin1 (UEA-1) (Vector labs), diluted in PBS containing 1% BSA. Anti-ANGPTL4 was detected by 1 h incubation with Alexa Fluor Õ 488 goat anti-rabbit IgG, UEA-1 was visualized using Alexa Streptavidin 647, and astrocytes were visualized using anti-glial fibrillary acid protein (GFAP)-Cy3 (Sigma Aldrich). To visualize amyloid deposits, sections were stained with 1% aqueous solution of Thioflavin S (Sigma Aldrich) for 10 min at room temperature. Sections were subsequently washed with an alcohol gradient and distilled water and mounted in Mowiol Õ (Sigma Aldrich).
Astrocyte culture and treatment
Primary human astrocytes (ScienCell) were grown until subconfluence in poly-L-lysine-coated 24-well plates in DMEM/ HAM-F12 (1:1) medium containing 10% (v/v) foetal calf serum, 100 IU/ml penicillin, and 50 mg/ml streptomycin. Cells were grown either at 1% O 2 (referred to as hypoxia) or at 21% O 2 (referred to as normoxia). The human astrocytoma cell line U373 was treated for 48 h with amyloid-b 1-42 peptide (Ab1-42) (rPeptide), dissolved as described previously, at a final concentration of 6 mM (de Jager et al., 2015) .
Generation of ANGPTL4 overexpressing astrocytoma cell lines
Lentiviral particles for transduction of the U373 astrocytic cell line were generated by calcium phosphate co-transfection of subconfluent human embryonic kidney (HEK) 293T cells with a human ANGPTL4 vector (abm) together with 
Quantitative PCR
Total RNA was isolated from primary human astrocytes or lentiviral transduced U373 or human brain endothelial cells using TRIzol Õ (Invitrogen). RNA concentration was determined using a Nanodrop spectrophotometer (Nanodrop technologies). cDNA synthesis was performed using a reverse transcription system kit (Promega). Quantitative PCR (qPCR) reactions were performed on a StepOne TM real-time PCR machine (Invitrogen) using SYBR Õ green detection. Primers for qPCR were obtained from Isogen Life Science. Primer sequences are given in Table 2 . Messenger RNA expression levels were normalized using 18s rRNA and GAPDH.
Western blot analysis
Protein was isolated from U373-ANGPTL4 and U373-EV astrocytes using RIPA lysis buffer containing protease and phosphate inhibitors (Roche). Equal amounts of protein were separated on 10% SDS-PAGE gel followed by transfer to nitrocellulose membranes for immunoblot analysis. Blots were blocked in a 1:1 (v/v) dilution of Odyssey Õ blocking buffer (Li-COR Biosciences) in PBS and incubated overnight at 4 C with the primary antibody against ANGPTL4 (Abcam). Detection of primary antibodies was performed by incubation with secondary IRDye Õ 800 antibodies (Li-COR Biosciences) for 1 h at room temperature. Signals were recorded and quantified using an Odyssey Õ infrared imaging system (LI-COR).
ELISA
U373-ANGPTL4 and U373-EV cells were cultured under normoxic conditions (21% O 2 ) for 24 h after which supernatants were collected. ANGPTL4 levels secreted in the supernatant were measured using the Human-ANGPTL4 Duoset ELISA kit (R&D Systems) according to the manufacturer's instructions.
MTS assay
Cell viability was assessed using the Cell Titre 96 Õ Aqueous One Solution Cell Proliferation Assay (MTS) (Promega) according to the manufacturer's protocol. In brief, U373-ANGPTL4 and U373-EV cells were cultured in a 96-well plate until they reached confluence. Cells were then incubated with MTS reagent for 1 h after which absorbance was measured at 490 nm using a 96 well plate reader (Bio-Rad).
hCMEC/D3 cell culture
The human brain endothelial cell line hCMEC/D3 was kindly provided by Prof. Dr Couraud (Institute Cochin, Universite Paris Descartes, Paris, France) (Weksler et al., 2005) . The cells were grown in EBM-2 medium (Lonza) supplemented with hEGF, hydrocortisone, GA-1000, VEGF, hFGF-B, R3-IGF-1, ascorbic acid and 2.5% foetal calf serum (Lonza) and cultured as described previously .
Endothelial migration assay
hCMEC/D3 were grown in EBM2 media supplemented with either rhANGPTL4 (1 mg/ml; R&D Systems), or with astrocyte conditioned medium (ACM) derived from U373-ANGPTL4 or U373-EV as a control. hCMEC/D3 migration was followed for 48 h, with an interval of 15 min, using a time-lapse microscope (Olympus IX81). Migration speed and distance travelled were analysed and quantified manually using tracking plugin and area selection-and measurement tools in Fiji/ImageJ software (v1.50).
3D in vitro sprouting assay
Human pericytes were isolated from human vena saphena magna in accordance with the Dutch guidelines for secondary use material. Pericytes were maintained in advanced Dulbecco's modified Eagle medium (Gibco), supplemented with 10% foetal bovine serum, 10% human serum, 2 mM L-glutamine and 1% penicillin/streptomycin (Lonza). Pericytes and hCMEC/D3 cells were suspended in a 1:20 ratio in RPMI media containing 0.25% (w/v) methylcellulose and plated on a square petri dish as a single drop. The plate was flipped and kept in the incubator to generate spheroids by this hanging drop technique. For in vitro sprouting assays, spheroids were harvested in RPMI medium containing 20% (v/v) heat inactivated human serum. After centrifugation at 800 rpm for 5 min, spheroids were resuspended in RPMI medium containing heat-inactivated human serum and 0.5% (w/v) methylcellulose. The spheroids were then transferred to ANGPTL4  ATG GCT CAG TGG ACT TCA AC  GCT ATG CAC CTT CTC CAG AC  GAPDH  CCA TGT TCG TCA TGG GTG TG  GGT GCT AAG CAG TTG GTG GTG  18sRNA  TAC CAC ATC CAA GGA AGG CAG CA  TGG AAT TAC CGC GGC TGC TGG CA  EFNA4  GCC CAG TGA CCT GAA ACT GT  TGC TCC TGC CGC TTC TTC  UNC5b CTT CAA GAT CCC ACT GTC CAT C GGT GGC AAA GTA ATT CAG GTA C Primers are listed as 5 0 -3 0 .
collagen matrices in eight-well m-Slides (IBIDI). To each well, 100 ml of RPMI containing 1 mg/ml rhANGPTL4 (R&D Systems) or ACM from U373-ANGPTL4 cells was added. Incubations with RPMI media or ACM from U373-EV cells served as controls. Spheroids were subsequently incubated at 37 C, 5% CO 2 , and 100% humidity during 16 h, after which the number of sprouts and sprout length was quantified using ImageJ (v1.50) image analysis software.
Patient samples
Patients were selected from the Amsterdam Dementia Cohort (van der Flier et al., 2014) . Diagnosis of Alzheimer's disease cases was performed following the NINDS-AIREN guidelines (McKhann et al., 1984) . Patients were further classified into Alzheimer's disease with and without microbleeds as observed by MRI. Patients exhibiting cognitive decline and small vessel disease were collectively grouped under vascular dementia. Patients that presented with cognitive decline, but performed well in psychiatric tests and showed a normal range in clinical assessment, were classified as subjective memory complaints. CSF and plasma were collected, processed and stored according to JPND-BIOMARKAPD guidelines. Alzheimer's disease CSF biomarkers (amyloid-b 42 , total tau and p-tau 181 ) were analysed as part of routine diagnostics (ELISA; Fujirobio) (Mulder et al., 2010) . Blood was collected from patients, coagulated at room temperature and centrifuged at 1800g for 10 min at 4 C. All subjects had given written consent and the ethical review board of VU University medical centre has approved this study. Demographic details are presented in Table 3 .
Statistical analysis
All statistical analyses were performed using SPSS version 22 (IBM Corp. Armonk, NY, USA). Group comparisons were performed using Kruskal-Wallis test, and correlation studies were conducted using Spearman's correlation test. P-values (two-tailed) were considered significant when lower than 0.05.
Data availability
The datasets analysed during the present study are not publicly available, but they are available from the corresponding author on reasonable request.
Results
ANGPTL4 is expressed by reactive astrocytes in post-mortem tissues with capillary CAA To analyse the expression of ANGPTL4, we performed immunohistochemical analysis of well characterized postmortem tissues of Alzheimer's disease cases with and without capillary CAA compared to age and gender matched non-demented controls (patient details in Table 1 ). Using Congo-Red, we detected vascular amyloid-b depositions in capillaries and larger cerebral vessels (Fig. 1A) . No amyloidb positive vessels were detected in non-demented controls.
ANGPTL4 immunoreactivity was mainly observed in the upper cortical layers and at the grey-white matter border in control brain samples. In addition, ANGPTL4 is strongly expressed throughout the white matter in control tissue (Fig. 1A) . In cases of Alzheimer's disease without signs of capillary CAA, ANGPTL4 expression also appears in deeper layers of the cortex (Fig. 1B) . In capillary CAA, we observed an overall increase in ANGPTL4 expression throughout the cortical layers with the most profound upregulation in areas with amyloid-laden vessels (Fig. 1C and D) . High magnification revealed star-shaped ANGPTL4-positive cells with the cellular morphology of astrocytes. Co-localization studies using the astrocyte marker glial fibrillary acid protein (GFAP) confirmed that ANGPTL4 is predominantly expressed by reactive astrocytes in close vicinity of vessels with amyloid deposition (Fig. 1E-Y) . Interestingly, immunohistochemical analysis of capillary CAA cases showed a global increase in expression of CA IX, a hypoxic marker (Proescholdt et al., 2005) (Supplementary Fig. 1A-C) .
ANGPTL4 is produced by human astrocytes under hypoxic conditions
To investigate the underlying mechanisms of enhanced astrocytic ANGPTL4 expression in capillary CAA cases, primary human astrocytes were cultured under various experimental conditions. Using this set-up, we detected a significant increase (P 5 0.05) in ANGPTL4 production in astrocytes cultured under hypoxic conditions (1% O 2 ) for 48 h (Fig. 2A) . In contrast, ANGPTL4 levels in astrocytes exposed to 6 mM amyloid-b 1-42 were not affected ( Fig. 2A and B).
ANGPTL4 does not influence astrocytic cellular behaviour
To assess the role of increased astrocytic expression of ANGPTL4 in the pathophysiology of capillary CAA, we created an ANGPTL4 overexpressing cell line using U373 astrocytoma cells (U373-ANGPTL4) with empty vector transduced U373 cells (U373-EV) as control. U373-ANGPTL4 cells showed a profound increase in ANGPTL4 mRNA levels relative to levels of the endogenous ANGPTL4 mRNA in U373-EV cells (Supplementary Fig. 2A ). Steady state intracellular levels of full-length as well as both proteolytically cleaved ANGPTL4 protein products were significantly increased in U373-ANGPTL4 as compared to Supplementary Fig. 2B ). Cumulative levels of secreted ANGPTL4 were measured in 24 h conditioned medium using an ELISA. A significant difference was found in levels of ANGPTL4 secreted from U373-ANGPTL4 cells (3 ng/ml) compared to U373-EV controls (not detectable) ( Supplementary Fig. 2C ). To assess the effect of ANGPTL4 on astrocyte proliferation and viability, we determined the proliferation rate of the U373-ANGPTL4 and U373-EV cells ( Supplementary Fig. 3A and B). Our results indicate that overexpression of ANGPTL4 in astrocytes leads to an increase in the levels of secreted ANGPTL4 without affecting cell proliferation or viability.
U373-EV (
ANGPTL4 induces brain endothelial cell migration and promotes angiogenesis
To study the effect of ANGPTL4 secreted by reactive astrocytes on brain microvascular endothelial cells, we first examined the migratory behaviour of human brain endothelial cells (hCMEC/D3) upon exposure to ANGPTL4. hCMEC/D3 cells were treated with astrocyte conditioned media (ACM) from U373-ANGPTL4 or U373-EV cells or exposed to 1 mg/ml of rhANGPTL4 and analysed for migration speed and distance travelled. We observed that hCMEC/D3 cells stimulated with rhANGPTL4 or with ACM from U373-ANGPTL4 showed a higher migration speed (P 5 0.01) and total distance covered (P 5 0.01) compared to controls. These findings indicate that ANGPTL4 affects endothelial cell motility (Fig. 3A-E) .
To assess the effect of ANGPTL4 on the angiogenic properties of brain endothelial cells, we analysed endothelial cell sprouting using 3D spheroids composed of hCMEC/D3 cells and human pericytes. Spheroids were treated with ACM derived from U373-ANGPTL4 or U373-EV cells or exposed to 1 mg/ml of rhANGPTL4 for 15 h. We observed that conditioned media from U373-ANGPTL4 cells or exposure to rhANGPTL4 significantly increased the length of sprouting vessels as well as the number of sprouts formed per spheroid, compared to controls ( Fig. 3F-K) . Upon further qPCR analysis of the expression of angiogenic markers in hCMEC/D3 treated with rhANGPTL4, we observed an increase in the expression of EphrinA4 and Unc-5 netrin receptor mRNA levels (data not shown).
Our observations on the angiogenic potential of ANGPTL4 were further confirmed in an in ovo chick chorioallantoic membrane (CAM) model by exposing the CAM to rhANGPTL4 and engrafting U373-ANGPTL4 cells onto the CAM (Supplementary Fig. 4) . Together, our data support a role of ANGPTL4 in induction of angiogenesis under cerebral pathological conditions associated with capillary CAA.
Increased microvascular density in post-mortem tissues of patients with capillary CAA To examine if increased expression of ANGPTL4 is associated with increased microvascular density in post-mortem tissues of patients with capillary CAA, we quantified the microvasculature. Our results showed an increased microvascular density, marked by expression of UEA-1, an established endothelial cell marker, in post-mortem tissues of capillary CAA patients (n = 9) as compared to non-demented controls (n = 9) (P 5 0.005) (Fig. 4A-C) . These results Figure 2 Increased ANGPTL4 expression by astrocytes under hypoxic conditions. Messenger RNA expression of ANGPTL4 was measured in primary astrocytes after 24 h of treatment with either 6 mM amyloid-b 42 or hypoxia (1% O 2 ). Expression was determined by real-time quantitative PCR, normalized to 18s RNA and shown as fold induction, relative to resting astrocytes (control) (A). Representative western blots demonstrating increased ANGPTL4 protein expression in hypoxia-treated astrocytes compared to non-treated and amyloid-b 42 treated astrocytes. -Tubulin was used as a protein loading control. -Tubulin normalized ANGPTL4 expression is shown as fold induction, relative to resting astrocytes (control) (B). Data are represented as mean AE SEM of at least three independent experiments with triplicate samples.
Ã P 5 0.05 by Student t-test.
ANGPTL4 in capillary CAA
provide further support for involvement of enhanced ANGPTL4 expression in the increased microvascular density observed in patients with capillary CAA.
Plasma ANGPTL4 levels are enhanced in vascular dementia patients
We next evaluated the potential of ANGPTL4 plasma levels as a biomarker in a memory clinic setting. Group comparison revealed a significant difference in plasma levels of ANGPTL4 (P 5 0.05). More specifically, we observed an elevation of plasma levels of ANGPTL4 in vascular dementia compared to controls (P 5 0.05) (Fig. 5) . We also observed a clear trend of increased ANGPTL4 levels in subjects with Alzheimer's disease and microbleeds compared to those with subjective memory complaints, although it did not reach statistical significance. Additionally, our results revealed no or a weak association of ANGPTL4 with clinical characteristics such as MiniMental State Examination (MMSE) scores and CSF levels of amyloid-b 42 , pTau and total tau levels ( Supplementary  Fig. 5A-D) .
Discussion
Cerebrovascular dysfunction is now widely recognized as a major contributor to the pathogenesis of capillary CAA. In this study, we reveal that the hypoxia-induced ANGPTL4 is highly upregulated in capillary CAA cases in areas with vascular amyloid deposition. ANGPTL4 is predominantly expressed by reactive astrocytes in capillary CAA patients and our in vitro data provide evidence that ANGPTL4 plays a key role in the induction of pathological vessel formation. Our results indicate that reactive astrocytes surrounding the amyloid laden micro-vessels under hypoxic conditions may be a predominant source of ANGPTL4.
Our in vitro studies demonstrate that ANGPTL4 induces a marked alteration in vessel sprouting and growth, illustrating a potential role of ANGPTL4 in pathological vessel formation. In addition, our data indicate that plasma levels of ANGPTL4 may serve as a marker for ongoing vascular changes, due to hypoxic conditions. For the first time, we show an increased expression of ANGPTL4 in astrocytes surrounding the vessels with amyloid deposits in well-defined post-mortem tissues of patients with capillary CAA compared to non-neurological controls. Our results demonstrate an increased reactivity of astrocytes adjacent to amyloid affected vessels, as detected by increased GFAP expression, which was also reported in previous studies (Kamphuis et al., 2014; Sofroniew and Vinters, 2010) . Increased reactivity of astrocytes may also have a profound effect on the proper function of the cerebral vasculature (Alvarez et al., 2013) . Recent reports further suggest the involvement of reactive astrocytes in altering dynamics of cerebral blood flow, resulting in local hypoxia (Zhang and Le, 2010; Salminen et al., 2017) . However, markers indicative of this pathological process remain largely unknown. Notably, expression of ANGPTL4 in peripheral tissues was found to be associated with hypoxia (Murata et al., 2009) . Accordingly, our experiments indicate that enhanced astrocytic ANGPTL4 results from local hypoxia rather than from a direct effect of amyloid on astrocytes.
Localized or ubiquitous deposition of amyloid in the cerebrovasculature causes a decrease in cerebral perfusion and promotes ischaemic damage and subsequent cognitive decline (Di Marco et al., 2015) . To compensate for low cerebral perfusion, an increase in neo-vascularization has been reported (Sonntag et al., 2007) . Hypoxia induced expression of VEGF and FGF2 was reported to be involved in [n = 13; 14.02 (23.55-8.44 )] are significantly higher compared to patients with subjective memory complaint (SMC) [n = 13; 8.15 (11.76-5.07) ] and compared to plasma levels in Alzheimer's disease patients without microbleeds (AD-MB) [n = 13; 8.63 (13.40-5.68 ) AE 5.0 ng/ml] (P = 0.06). Enhanced levels of ANGPL4 were detected in Alzheimer's disease cases with microbleeds [AD + MB; n = 13; 8.7 (15.43-7.51) ng/ml], albeit not significantly compared to patients with subjective memory complaints. enhanced cerebral angiogenesis (Pfeifer et al., 2002) . However, possible involvement of additional factors in this process has remained obscure. In our current study, we observed in various in vitro models that pro-angiogenic effects of conditioned medium from ANGPTL4-overexpressing astrocytes were similar to the effects of rhANGPTL4. Thus, our data consistently point at astrocyte derived ANGPTL4 as a novel angiogenic factor in capillary CAA. Accordingly, recent work has demonstrated a role of ANGPTL4 in angiogenesis in Kaposi sarcoma and in vascular tumours (Hu et al., 2011; Liao et al., 2017) . Furthermore, our results are in accordance with a study indicating the angiogenic potential of ANGPTL4 produced by retinal Muller cells in the induction of neovascularization in proliferative diabetic retinopathy (BabapoorFarrokhran et al., 2015; Hu et al., 2016) and during tendon injury (Mousavizadeh et al., 2016) . Our in ovo data further confirm the angiogenic potential of ANGPTL4 and suggest that it contributes to formation of an abnormal vasculature. Although we cannot exclude involvement of other potential angiogenic factors in enhanced pathological neovascularization in Alzheimer's related diseases (Sala et al., 2002; Martin et al., 2011) , our results suggest that ANGPTL4 plays a pivotal role in this process.
Our results revealed an increase in microvascular density in capillary CAA patients as compared to non-demented control. Previous post-mortem research has shown an increase in microvascular density in the hippocampus of Alzheimer's disease patients (Vagnucci and Li, 2003; Biron et al., 2011; Jefferies et al., 2013) . In the Honululu-Asian Ageing Study (HAAS), evidence was found for enhanced angiogenesis in different regions of the brain affected by cerebral amyloid (Pfeifer et al., 2002; Gelber et al., 2012) , although underlying causes remain unknown. Based on our results, increased microvascular density may be the result of elevated ANGPTL4 levels observed in capillary CAA cases.
Recent studies indicate that plasma ANGPTL4 levels may serve as a potential biomarker reflecting enhanced angiogenesis in oncological pathologies such as renal cell carcinoma or hepatocellular carcinoma (Dong et al., 2017; El-Shal et al., 2017; Hata et al., 2017) . Elevated levels of ANGPTL4 were also detected in the aqueous and vitreous fluids of proliferative diabetic retinopathy patients (Babapoor-Farrokhran et al., 2015) . In both pathologies, hypoxia plays a major role. Accordingly, elevated ANGPTL4 plasma levels in patients with vascular dementia may be indicative for hypoperfusion-associated hypoxia, which is recognized as major factor in the aetiology of cerebrovascular disease (Iadecola, 2013) . Our current data show that plasma ANGPTL4 levels are significantly higher in vascular dementia patients compared to cases with subjective memory complaints, and cases with Alzheimer's disease and microbleeds showed a trend in the increased levels when compared to controls. Our study is limited by a relatively small cohort and future studies including larger patient groups are needed to confirm the clinical potential of plasma ANGPTL4 levels in vascular dementia diagnosis.
Our data define a role for ANGPTL4 in angiogenic vascular pathology associated with capillary CAA. Epidemiological studies showed that the prolonged use of statins, anti-inflammatory drugs and calcium channel blockers are beneficial for the treatment of Alzheimer's disease, partly due to their anti-angiogenic properties (Jick et al., 2000; Nimmrich and Eckert, 2013; Wang et al., 2015) . The Rotterdam epidemiological study and population study on elderly Mexican-Americans reported that statin intake reduces the chances of dementia and cognitive impairment, elucidating their neuro-protective effect (Cramer et al., 2008; Haag et al., 2009 ). In conclusion, our data not only provide evidence for a novel role of ANGPTL4 in the pathogenesis of capillary CAA, but also indicate its use as a biomarker for pathological angiogenesis. Furthermore, our study suggests that counteracting the detrimental effect of ANGPTL4 through the development of specific anti-ANGPTL4 therapy may open new avenues to fight capillary CAA.
